Selpercatinib (RETEVMO) approved by FDA in May 2020 for the treatment of non-small cell lung cancer and some types of thyroid cancers in people whose tumors have an alteration in a specific RET gene. It is a tyrosine kinase inhibitor that blocks a type of enzyme and helps prevent the cancer cells from growing. Selpercatinib contains pyrazolo[1,5-a]pyridine moiety in its backbone. We have made a set of Building Blocks, which contain such part – the perfect start for your research!